Brief: LegoChem Biosciences, Amgen Collaborates For Development Of Antibody-Drug Conjugates
23/12/2022 12:04
Dec 23 (Reuters) - LegoChem Biosciences Inc 141080.KQ :
* LEGOCHEM BIOSCIENCES AND AMGEN ENTER INTO A MULTI-TARGET
RESEARCH COLLABORATION AND LICENSE AGREEMENT FOR THE DEVELOPMENT
OF ANTIBODY-DRUG CONJUGATES
* LEGOCHEM BIOSCIENCES INC- LCB ELIGIBLE TO RECEIVE UP TO
USD 1.25
BILLION
* LEGOCHEM BIOSCIENCES INC - UNDER AGREEMENT, CO ELIGIBLE
FOR
TIERED ROYALTIES AS A PERCENTAGE OF WORLDWIDE COMMERCIAL SALES
BY AMGEN
Source text for Eikon: ID:nBw7hcB64a
Further company coverage: 141080.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LigaChem Biosciences
See all newsBrief: Ligachem Biosciences To Issue 170 Billion Won Worth Of Convertible Bonds
Brief: Ligachem Biosciences - Issues 2.21 Million New Preferred Shares
Brief: Ligachem Biosciences To Divest 5 Billion Won Worth Of Own Shares
Brief: Ligachem Biosciences To Divest 17 Billion Won Worth Of Own Shares
Brief: Legochem Biosciences To Conduct Capital Increase Of 470 Billion Won For Operational Funds